SCHEMBL7258713

SCHEMBL7258713

Nc1ncc2ccccc2c1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
GPR3 P46089 1/20 0.47
F12 P00748 1/20 0.45
PLAU P00749 1/20 0.45
NCF1 P14598 1/20 0.45
NOS3 P29474 1/20 0.45
NOS1 P29475 1/20 0.45
NOS2 P35228 1/20 0.45
BACE1 P56817 1/20 0.45
PDPK1 O15530 1/20 0.42
PRKCZ Q05513 1/20 0.38
ALDH1A1 P00352 4/20 0.37
CYP3A4 P08684 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
TSHR P16473 1/20 0.37
KEAP1 Q14145 1/20 0.37
PI4KA P42356 2/20 0.36
PI4K2B Q8TCG2 2/20 0.36
PI4K2A Q9BTU6 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18848481 0.78 KDM4E (0.50) KDM4EGPR3F12PLAUNCF1
SCHEMBL28301397 0.78 KDM4E (0.50) KDM4EGPR3F12PLAUNCF1
SCHEMBL25307350 0.76 CLK1 (0.47) KDM4EALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL30381839 0.76 LMNA (0.44) KDM4EALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL25303924 0.76 LMNA (0.44) KDM4EALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL12490240 0.75 KDM4E (0.47) KDM4EGPR3F12PLAUNCF1
SCHEMBL16110845 0.75 SCN9A (0.54) KDM4EGPR3PDPK1ALDH1A1HPGD
SCHEMBL15401178 0.75 KDM4E (0.47) KDM4EGPR3F12PLAUNCF1
SCHEMBL16836457 0.75 KDM4E (0.47) KDM4EGPR3PDPK1ALDH1A1CYP3A4
SCHEMBL558613 0.75 KDM4E (0.47) KDM4EGPR3F12PLAUNCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 EP disclosed
WO-2024249291-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF CASMA THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
EP-4400497-A1 3CLPRO PROTEASE INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-07-17 EP disclosed
WO-2023169453-A1 HETEROAROMATIC RING-CONTAINING ALKYNYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海药物研究所 2023-09-14 WO disclosed
CN-116730978-A Compound containing heteroaromatic ring alkynyl, preparation method and application thereof 中国科学院上海药物研究所 2023-09-12 CN disclosed
WO-2023036140-A1 3CLPRO PROTEASE INHIBITOR 上海齐鲁制药研究中心有限公司 2023-03-16 WO disclosed
US-20220324880-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-13 US disclosed
WO-2020251974-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 WO disclosed
WO-2020251974-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 WO disclosed
US-20190209548-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, BALTIMORE 2019-07-11 US disclosed
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2017-06-22 US disclosed
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2017-06-22 US disclosed
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2017-06-22 US disclosed
US-9604997-B2 Peri-carbinols ALDEYRA THERAPEUTICS, INC. (US) 2017-03-28 US disclosed
WO-2016014674-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2016-01-28 WO disclosed
WO-2016014674-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2016-01-28 WO disclosed
US-20150344432-A1 PERI-CARBINOLS Ricerca Biosciences, LLC 2015-12-03 US disclosed
EP-2935220-A1 PERI-CARBINOLS Aldeyra Therapeutics, Inc. (US) 2015-10-28 EP disclosed
WO-2014100425-A1 PERI-CARBINOLS ALDEXA THERAPEUTICS, INC. (US) 2014-06-26 WO disclosed
WO-2003024931-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344432-A1 PERI-CARBINOLS PLIN1, PLIN3, PLIN5 KDM4E 3484/4885GPR3 734/4885F12 354/4885
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME MCL1, DPYD, TOP2B KDM4E 1772/4885GPR3 4678/4885F12 4636/4885
US-20220324880-A1 SMARCA INHIBITORS AND USES THEREOF SMARCA1, SMARCE1, PBRM1 KDM4E 648/4885GPR3 4298/4885F12 2043/4885
US-20190209548-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME MCL1, DPYD, TOP2B KDM4E 1772/4885GPR3 4678/4885F12 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.